Clinical trial NCT03749577: Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's Phenomenon
Official title: Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's Phenomenon
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Raynaud Phenomenon
Keywords: l-citrullin
beetroot juice
Raynaud's phenomenon
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
Collaborators: name: University Hospital, Rouen
First posted: 2018-11-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The investigators aim at comparing the efficacy of a 2 weeks supplementation by L-citrulline or beetroot juice to L-citrulline placebo or denitrated beetroot juice respectively on Raynaud's phenomenon severity. Raynaud's phenomenon severity will be assessed through the Raynaud Condition Score, daily frequency of attacks or cumulative attack duration (expressed as min) daily collected by patients in a diary. Each Volunteer will choose his own main outcome among these 3 criteria.

Detailed description: Raynaud's phenomenon (RP) is a clinical condition that follows an exaggerated vasoconstriction of extremities in response to a cold or emotional stress. Microvascular dysfunction and alteration of the endothelial NO-dependent vasodilatation pathway through NO synthases (NOS) represents one of the main mechanisms.

A pharmacological treatment in RP is proposed to patients when conservative measures are not efficient enough to control the symptoms: calcium channel blockers remains the first line, phosphodiesterase type 5 inhibitors as a second line treatment, while intravenous iloprost remains restricted to patients with digital ischaemia. Vasodilator therapies are commonly associated with side effects due to the non-specific systemic vasodilation that often result in permanent discontinuation. Many patients prefer complementary and alternative therapies, but none has proven its efficacy. Therefore, there is still room for improvement in the treatment of RP, and research is needed in this area.

Eligibility criteria: Inclusion Criteria:

* BMI \> 18
* Active Raynaud's Phenomenon characterized by a clinical history of Raynaud's

  1. Primary RP or secondary to limited (LSSc), limited or diffuse cutaneous scleroderma (lcSSc or dcSSc) according to the criteria of Leroy and Medsger.
  2. At least 1 RP attacks per week and a specific finger patient picture in RP attack (assessed over the 2 weeks preceding inclusion)
* Stable disease over the previous two months (i.e. recent diagnosis of SSc will be excluded)
* Patients insured by a social security scheme or beneficiaries of such a scheme
* Patients who have dated and signed the informed consent form

Exclusion Criteria:

* Uncontrolled hypertension, uncontrolled diabetes mellitus, uncontrolled angina
* Haemodynamic instability
* Pregnancy (or considering pregnancy in next 4 months) or breast feeding
* Subject in an exclusion period from another study,
* Subject under administrative or judicial supervision
* Subject not able to be contacted in case of emergency

Primary outcomes:
measure: Change in Raynaud Condition Score
timeFrame: first winter: inclusion visit week 2, week 7, week 13, week 19; second winter: inclusion visit week 2,week 7, week 13, week 19
measure: Frequency of RP
timeFrame: 7 days (An attack is defined as an episode of pallor or cyanosis (with or without pain,tingling or numbness). The number of attacks is self-reported every day and averaged over 7-day periods)
measure: Change in cumulative attack duration
timeFrame: first winter: inclusion visit week 2, week 7, week 13, week 19; second winter: inclusion visit week 2,week 7, week 13, week 19
Secondary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
timeFrame: first winter: week 2, 4, 5, 7, 13, 19; second winter: week 2, 4, 5, 7, 13, 19
measure: Plasma concentration of L-arginine/ADMA ratio
timeFrame: first winter: week 2, 4, 5, 7; second winter: week 2, 4, 5, 7
measure: Plasma concentration of nitrites
timeFrame: first winter: week 2, 4, 5, 7; second winter: week 2, 4, 5, 7
measure: Plasma concentration of L-arginine
timeFrame: first winter: week 2, 4, 5, 7; second winter: week 2, 4, 5, 7
measure: Urinary GMPc
timeFrame: first winter: week 2, 4, 5, 7; second winter: week 2, 4, 5, 7
Other outcomes:
Locations:
city: Grenoble
country: France
facility: Grenoble University Hospital
Study officials:
affiliation: Grenoble University Hospital, Clinical Pharmacology Department
name: Jean-Luc Cracowski, MD
role: PRINCIPAL_INVESTIGATOR
References: